September 1, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 

 Headline News

Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). more info >>
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Yokogawa Electric announced that its confocal image single-cell drug discovery support system has been selected for the Japan Science and Technology Agency's (JST) next-generation technology transfer program (NexTEP). more info >>
ACN Newswire
 Press Release News

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. (Aug 20, 2014)
Eisai Co., Ltd. announced today that it has submitted applications to regulatory authorities in the U.S. and Europe (the FDA and EMA respectively) for the indication expansion of its in-house developed antiepileptic drug Fycompa as an adjunctive treatment of primary generalized tonic-clonic seizures (PGTC). more info >>
Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan (Aug 18, 2014)
Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai. more info >>
University of Tokyo's RCAST, Fujitsu, and Kowa Successfully Generate a Novel Active Compound Targeting Cancer Using IT-based Drug Discovery Technology (Aug 7, 2014)
The University of Tokyo's Research Center for Advanced Science and Technology (RCAST), Fujitsu Limited, and Kowa Company, Ltd. today announced that they have used IT-based drug discovery technology to successfully generate a novel pharmacologically active compound with the potential to be developed into a candidate for an anticancer drug. more info >>
EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment (July 31, 2014)
Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency (EMA) for its in-house developed anticancer agent lenvatinib mesylate in the treatment of radioiodine-refractory differentiated thyroid cancer. more info >>
MHI Receives Order for "Vero4DRT" Radiation Therapy System For New Cutting-edge Medical Facility in Hiroshima Prefecture (July 24, 2014)
Mitsubishi Heavy Industries, Ltd. (MHI) has received an order for the "Vero4DT," a radiation therapy system featuring dynamic tracking irradiation capability - marketed as the "MHI-TM2000 Linear Accelerator" - for the Hiroshima High-precision Radiotherapy Center, a cutting-edge cancer radiotherapy facility slated to open in Hiroshima Prefecture in Autumn 2015. more info >>
 Global Press Release

Understanding and Improving the Body's Fight Against Pathogens (Sept 1, 2014)

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. (Aug 20, 2014)

Novel Gene Predicts Both Breast Cancer Relapse and Response to Chemotherapy (Aug 20, 2014)

Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan (Aug 18, 2014)

Carbon Nanotubes and Near-infrared Lasers Promise a Cost Effective Solution for Cell Membrane Manipulation (Aug 15, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)